Literature DB >> 1592338

Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-alpha.

J Xu1, D Brown, T Harrison, Y Lin, G Dusheiko.   

Abstract

Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-alpha therapy. Fifteen carriers (nine responders and six nonresponders) who were treated with interferon-alpha were examined. Serum samples were collected before and after therapy. After extraction of DNA, the precore region was amplified by the polymerase chain reaction, and the product was identified by gel electrophoresis and ethidium bromide staining and then Southern blotting and molecular hybridization. The amplified products in all patients were asymmetrically amplified by a modified polymerase chain reaction, and the precore region was directly sequenced. All patients were HBV DNA positive initially. Circulating HBeAg-negative mutants were not identified before treatment in either responders or nonresponders. All nine responders were negative for HBV DNA in serum by dot blot during or after treatment, but seven remained positive by polymerase chain amplification and Southern-blot hybridization. All of the nonresponders remained positive for HBV DNA by dot blot. A silent mutation involving the substitution of an A for G at position 1888 was found in seven carriers; however, no HBeAg-negative mutants were detected in the follow-up of either responders or nonresponders to interferon-alpha.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592338     DOI: 10.1002/hep.1840150605

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

1.  Nucleotide sequence analysis of precore and proximal core regions in patients with chronic hepatitis B treated with interferon.

Authors:  T Laskus; J Rakela; D H Persing
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

2.  Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion.

Authors:  Chia-Ming Chu; Chau-Ting Yeh; Ching-Song Lee; I-Shyan Sheen; Yun-Fan Liaw
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

Review 3.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

4.  Hepatitis B virus persistence after recovery from acute viral hepatitis.

Authors:  T I Michalak; C Pasquinelli; S Guilhot; F V Chisari
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

5.  Universal emergence of precore mutant hepatitis B virus along with seroconversion to anti-HBe irrespective of subsequent activity of chronic hepatitis B.

Authors:  K C Koh; H S Lee; C Y Kim
Journal:  Korean J Intern Med       Date:  1994-07       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.